LSE:PRTC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States.


Snowflake Analysis

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has PureTech Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRTC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.5%

PRTC

-0.2%

GB Life Sciences

-2.5%

GB Market


1 Year Return

15.8%

PRTC

-7.0%

GB Life Sciences

-16.0%

GB Market

Return vs Industry: PRTC exceeded the UK Life Sciences industry which returned -7% over the past year.

Return vs Market: PRTC exceeded the UK Market which returned -16% over the past year.


Shareholder returns

PRTCIndustryMarket
7 Day1.5%-0.2%-2.5%
30 Day5.7%-1.4%-4.0%
90 Day3.2%15.0%4.9%
1 Year15.8%15.8%-6.5%-7.0%-12.1%-16.0%
3 Year117.8%117.8%1.0%-0.2%-5.4%-17.1%
5 Year72.1%72.1%26.9%24.8%11.6%-13.4%

Price Volatility Vs. Market

How volatile is PureTech Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PureTech Health undervalued compared to its fair value and its price relative to the market?

2.37x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PRTC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PRTC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PRTC is good value based on its PE Ratio (2.4x) compared to the GB Life Sciences industry average (48.8x).

PE vs Market: PRTC is good value based on its PE Ratio (2.4x) compared to the UK market (14.9x).


Price to Earnings Growth Ratio

PEG Ratio: PRTC's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PRTC is good value based on its PB Ratio (1.5x) compared to the GB Life Sciences industry average (3.6x).


Next Steps

Future Growth

How is PureTech Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-54.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRTC's earnings are forecast to decline over the next 3 years (-54.6% per year).

Earnings vs Market: PRTC's earnings are forecast to decline over the next 3 years (-54.6% per year).

High Growth Earnings: PRTC's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PRTC's revenue is expected to decline over the next 3 years (-47.7% per year).

High Growth Revenue: PRTC's revenue is forecast to decline over the next 3 years (-47.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRTC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has PureTech Health performed over the past 5 years?

66.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRTC has a large one-off gain of $629.1M impacting its December 31 2019 financial results.

Growing Profit Margin: PRTC became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: PRTC has become profitable over the past 5 years, growing earnings by 66% per year.

Accelerating Growth: PRTC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PRTC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (8.4%).


Return on Equity

High ROE: PRTC's Return on Equity (56.3%) is considered outstanding.


Next Steps

Financial Health

How is PureTech Health's financial position?


Financial Position Analysis

Short Term Liabilities: PRTC's short term assets ($168.8M) exceed its short term liabilities ($139.2M).

Long Term Liabilities: PRTC's short term assets ($168.8M) exceed its long term liabilities ($151.6M).


Debt to Equity History and Analysis

Debt Level: PRTC's debt to equity ratio (0.2%) is considered satisfactory.

Reducing Debt: PRTC had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: PRTC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if PRTC's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is PureTech Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRTC's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Daphne Zohar (49yo)

no data

Tenure

US$5,792,677

Compensation

Ms. Daphne Zohar is the Founder of PureTech Health plc and serves as its Chief Executive Officer, Managing Partner and Executive Director. Ms. Zohar co-founded Tal Medical, Inc. in 2010. She was a Director ...


CEO Compensation Analysis

Compensation vs Market: Daphne's total compensation ($USD5.79M) is above average for companies of similar size in the UK market ($USD1.21M).

Compensation vs Earnings: Daphne's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Daphne Zohar
Founderno dataUS$5.79m4.27% $33.6m
Robert Langer
Co-Founder & Non-Executive Directorno dataUS$110.00k1.03% $8.1m
Stephen Muniz
COO, Secretary & Executive Director5.5yrsUS$2.39m1.01% $8.0m
Bharat Chowrira
President and Chief of Business & Strategy3.33yrsno datano data
David Elmaleh
Co-Founder & Senior Advisorno datano datano data
Joseph Bolen
Chief Scientific Officer3.75yrsno datano data
Allison Talbot
Vice President of Communications & Investor Relationsno datano datano data
Eric Elenko
Chief Innovation Officer3.75yrsno datano data
Spencer Ball
Senior Vice President of Talentno datano datano data
Joep Muijrers
Chief of Portfolio Strategy0.50yrno datano data

3.8yrs

Average Tenure

52.5yo

Average Age

Experienced Management: PRTC's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daphne Zohar
Founderno dataUS$5.79m4.27% $33.6m
Robert Langer
Co-Founder & Non-Executive Directorno dataUS$110.00k1.03% $8.1m
Stephen Muniz
COO, Secretary & Executive Director5.5yrsUS$2.39m1.01% $8.0m
David Elmaleh
Co-Founder & Senior Advisorno datano datano data
Christopher Viehbacher
Independent Non-Executive Chairman of the Board0.83yrUS$107.07k0.36% $2.8m
Marjorie Morris Scardino
Senior Independent Directorno dataUS$90.00k0.28% $2.2m
John LaMattina
Independent Non-Executive Director11.5yrsUS$105.00k0.53% $4.2m
R. Anderson
3.75yrsno datano data
James Collins
4.67yrsno datano data
Frederick Frank
Senior Advisorno datano datano data

4.7yrs

Average Tenure

69.5yo

Average Age

Experienced Board: PRTC's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PRTC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PureTech Health plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PureTech Health plc
  • Ticker: PRTC
  • Exchange: LSE
  • Founded: 2015
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£786.587m
  • Shares outstanding: 285.51m
  • Website: https://www.puretechhealth.com

Number of Employees


Location

  • PureTech Health plc
  • 6 Tide Street
  • Suite 400
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRTCLSE (London Stock Exchange)YesOrdinary SharesGBGBPJun 2015
PTCH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2015
PRTCLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPJun 2015

Biography

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer’s and Parkinson’s diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/10 20:49
End of Day Share Price2020/07/10 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.